Debug Stats | ### Total Build Time: 52 ms 44.062 KB CONCEPT_NAME gt=3 ms Completed: 3 ms rowSize= 342 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 650 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=0 Completed: 0 ms rowSize= 187 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=5 ms Completed: 5 ms rowSize= 563 bytesCONCEPT_CHILDREN gt=0 Completed: 0 ms rowSize= 8 bytesCONCEPT_ANCESTRAL_ROOTS gt=8 ms Completed: 8 ms rowSize= 4.090 KBCONCEPT_RELATIONSHIPS gt=26 ms Completed: 26 ms rowSize= 15.764 KBCONCEPT_GENES gt=8 ms Completed: 8 ms rowSize= 21.315 KBCONCEPT_XREFS gt=2 ms Completed: 2 ms rowSize= 1.156 KBCONCEPT_ANCILLARY gt=0 Completed: 0 ms rowSize= 14 bytes- Reload Stats
|
Relationships (53)
Relation Types: diso_to_anat : 22 diso_to_chem : 2 diso_to_diso : 29
Relationships: none : 9 associated_with : 3 is_abnormal_cell_of_disease : 7 is_associated_anatomic_site_of : 1 is_finding_of_disease : 3 is_normal_cell_origin_of_disease : 5 is_normal_tissue_origin_of_disease : 2 is_not_abnormal_cell_of_disease : 1 is_not_normal_cell_origin_of_disease : 3 is_primary_anatomic_site_of_disease : 3 isa : 7 may_be_associated_disease_of_disease : 3 may_be_finding_of_disease : 3 may_be_molecular_abnormality_of_disease : 2 permuted_term_of : 1 | |
DISO_to_DISO | 53 | |
Cutaneous tumor C0037286 | DISO_to_DISO | 15 | |
Complication Aspects C1171258 | DISO_to_DISO | 14 | |
Cutaneous tumor C0037286 | DISO_to_DISO | 14 | |
Ki-1+ Anaplastic Large Cell Lymphoma C0206180 | DISO_to_DISO | 11 | |
Complication Aspects C1171258 | DISO_to_CHEM | 10 | |
Antigens, CD30 C0054950 | DISO_to_CHEM | 8 | |
Antigens, CD30 C0054950 | DISO_to_DISO | 8 | |
Ki-1+ Anaplastic Large Cell Lymphoma C0206180 | DISO_to_DISO | 8 | |
Mycosis Fungoides C0026948 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Abnormal Hematopoietic and Lymphoid Cell C1510725 | DISO_to_ANAT | | is_normal_cell_origin_of_disease |
Activated Skin-Homing T-Lymphocyte C1519602 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Atypical lymphocyte C0221277 | DISO_to_ANAT | | is_normal_tissue_origin_of_disease |
HEMOLYMPHORETICULAR TISSUE C1512398 | DISO_to_ANAT | | is_primary_anatomic_site_of_disease |
Hematopoietic and Lymphatic System C1512394 | DISO_to_ANAT | | is_normal_cell_origin_of_disease |
Hematopoietic and Lymphoid Cell C1512385 | DISO_to_ANAT | | is_associated_anatomic_site_of |
Integumentary System C0037267 | DISO_to_ANAT | | is_primary_anatomic_site_of_disease |
Lymphatic System C0024235 | DISO_to_ANAT | | is_normal_tissue_origin_of_disease |
Lymphatic Tissue C0024296 | DISO_to_ANAT | | is_normal_cell_origin_of_disease |
Lymphocyte C0024264 | DISO_to_ANAT | | is_not_normal_cell_origin_of_disease |
Myeloid Cells C0887899 | DISO_to_ANAT | | is_not_abnormal_cell_of_disease |
Neoplastic B-Lymphocyte C1513929 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Neoplastic Cell C0597032 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Neoplastic Hematopoietic and Lymphoid Cell C1513983 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Neoplastic Lymphocyte C1514011 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Neoplastic T-Lymphocyte C1514109 |
|
Genes (9)
Species: human : 9 | |
Human | PTPN22 | 26191 | protein tyrosine phosphatase, non-receptor type 22 (lymphoid) | Spontaneous disease also requires homozygosity for lyp/iddm1, which causes lymphopenia. Haplotype tag single nucleotide polymorphism analysis of the human orthologues of the rat type 1 diabetes genes Ian4 (Lyp/Iddm1) and Cblb. T cells from BB-DP rats show a unique cytokine mRNA profile associated with the IDDM1 susceptibility gene, Lyp. | Human | TNFRSF4 | 7293 | tumor necrosis factor receptor superfamily, member 4 | Loss of CD134 expression in LyP may be a marker of an increased risk of second lymphoid malignancy. OBJECTIVES: To determine CD134 expression in cutaneous lymphoma and benign inflammatory disorders.METHODS: Biopsy material was obtained from patients with lymphomatoid papulosis (LyP, n = 42), mycosis fungoides (n = 21), Jessner;s infiltrates (n = 10) and non-specific dermatitis (n = 14). There was no correlation between the magnitude of CD134 expression and the histological type or the proportion of G2 + S cells in LyP. CD134 immunoreactivity was lower than expected in patients with LyP and another lymphoid malignancy (P _lt_ 0.001, Fisher;s exact test). OBJECTIVES: To determine CD134 expression in cutaneous lymphoma and benign inflammatory disorders.METHODS: Biopsy material was obtained from patients with lymphomatoid papulosis (LyP, n = 42), mycosis fungoides (n = 21), Jessner;s infiltrates (n = 10) and non-specific dermatitis (n = 14). Expression of T-cell activation marker CD134 (OX40) in lymphomatoid papulosis. CONCLUSIONS: CD134 is strongly expressed in a proportion (38%) of patients with LyP, but not in mycosis fungoides or benign lymphocytic infiltrations. | Human | S100A9 | 6280 | S100 calcium binding protein A9 | The discrepancy among KP1, MAC387 and LN-5 reactivities may represent the concurrent occurrence of ALCL and lymphomatoid papulosis. | Human | NPM1 | 4869 | nucleophosmin (nucleolar phosphoprotein B23, numatrin) | Fusion of the NPM and ALK genes was detected in three of 18 patients with ALCL who had amplifiable DNA (17%, 95% confidence intervals 4% to 41%), but not in any patients with other NHL, HD, or lymphomatoid papulosis. | Human | JUNB | 3726 | jun B proto-oncogene | JunB was also expressed in all cases of classical Hodgkin lymphoma, cutaneous anaplastic large cell lymphoma and CD30+ diffuse large B-cell lymphoma, and in lymphomatoid papulosis. JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. | Human | CCR4 | 1233 | chemokine (C-C motif) receptor 4 | CCR4 was expressed in 11 of 12 (92%) cases of PCALCL, but in only two of 13 (15%) cases of LyP. CD30 cells exclusively expressed CCR4 in anaplastic large-cell lymphoma, and CXCR3 and/or CCR4 in lymphomatoid papulosis. To find out whether this mechanism might also be operative in CD30+ malignant lymphomas other than HD, TARC and CCR4 expression was investigated by immunohistochemistry on paraffin and frozen-tissue sections of 39 nodal CD30+ anaplastic large cell lymphomas (ALCL), including 27 ALK-negative and 12 ALK-positive ALCL, 25 primary cutaneous CD30+ ALCL, including 11 patients with lymphomatoid papulosis, and 31 cases of HD. | Human | TNFSF8 | 944 | tumor necrosis factor (ligand) superfamily, member 8 | The results suggest that progression of LyP to lymphoma is associated with escape of lymphoma cells from growth regulation by TGF-beta and CD30 ligand. Because transforming growth factor-beta (TGF-beta) and CD30 ligand inhibit the growth of normal lymphocytes and can be detected in regressing lesions of LyP, we tested the effect of these cytokines on cell lines clonally derived from LyP in the progression to systemic lymphoma. In a recent study, a selective increase in CD30 ligand expression in regressing lesions of lymphomatoid papulosis and cutaneous CD30+ anaplastic large cell lymphoma was shown, suggesting that activation of the CD30 signaling pathway may be responsible for tumor regression, whereas no difference in Fas/Fas ligand expression was found between regressing and nonregressing lesions. Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand. | Human | TNFRSF8 | 943 | tumor necrosis factor receptor superfamily, member 8 | Single-cell analysis of CD30+ cells in lymphomatoid papulosis demonstrates a common clonal T-cell origin | Human | CASP2 | 835 | caspase 2, apoptosis-related cysteine peptidase | Proximal to Lyp are the genes caspase-2 (Casp2) and pancreatic trypsin 1 (Prss1), while neuropeptide Y (Npy) is the closest distally positioned gene. This raises the question whether the human homologue of Lyp is linked to CASP2/PRSS1 or to NPY. |
|